Inside Incyte’s Jakafi Performance in 2Q17


Aug. 23 2017, Updated 9:07 a.m. ET


Incyte’s (INCY) Jakafi (ruxolitinib) is approved by the FDA (US Food and Drug Administration) for the treatment of myelofibrosis and polycythemia vera, which are both rare types of blood cancer. Jakafi is the only FDA-approved drug for the treatment of these conditions.

Revenues from Jakafi in US markets rose ~32.6% to $276.0 million in 2Q17, up from $208.1 million in 2Q16. This growth was driven by the strong demand for the drug, which resulted in increased sales volumes in 2Q16.

Article continues below advertisement

Jakafi and its importance

Incyte holds the marketing rights for US markets with itself, while it has entered into a collaborative agreement with Novartis (NVS) for the marketing of Jakafi outside of US markets. Novartis markets the drug outside the US as Jakavi.

Notably, Jakafi is the first product from Incyte’s portfolio that was approved by the FDA. Jakafi is also the first oral JAK inhibitor approved by the FDA.

Incyte received royalty revenues of $33.9 million from Jakavi sales in 2Q17 by Novartis. Incyte holds the patent rights for the composition of matter and the use of Jakafi (ruxolitinib) up to November 2026, and it has also received extensions for these patents up to 2027.

To divest company-specific risks, investors can consider ETFs like the iShares Global Healthcare ETF (IXJ), which has 0.5% of its total assets in Incyte (INCY). IXJ also has 8.2% in Johnson & Johnson (JNJ), 3.9% in Merck (MRK), and 2.2% in GlaxoSmithKline (GSK).


More From Market Realist

  • SemiLEDS logo over LED lighting
    Company & Industry Overviews
    There's Still Time to Get in on SemiLEDS (LEDS) Stock
  • Trader on the NYSE
    Company & Industry Overviews
    What Are the Most Expensive Stocks Ever?
  • Michelob Ultra beer
    Company & Industry Overviews
    AB InBev Is the Top Beer Brand Worldwide—Is It a Monopoly?
  • Businesswoman looking out a window
    Company & Industry Overviews
    Shifting Focus: Three Women Investing Funds in 2021
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.